t o prevent misunderstanding, I begin at the end: the point of this Editorial is to celebrate and welcome Editor Barbara Gilchrest's decision to elevate epidemiology to one of the (now) 12 permanent discipline-based sections in the Journal. This decision is certainly overdue; it should have been made by the previous Editor-in-Chief, but I am quite pleased to see it happen now. In fact, Tamar Nijsten (the new section editor, a wise choice) and Rob Stern have made my assignment easier through their comprehensive review of cutaneous epidemiology published in the 75th-anniversary special edition of the Journal (Nijsten and Stern, 2012) . Sufficient reasoning can be found in that review, although my reasoning follows the following, somewhat different, track.
1. Epidemiology is a scientific discipline. Dating back to the work of John Snow on epidemic cholera in London in the eighteenth century (Hempel, 2013) , epidemiological studies have provided powerful insight into the pathogenesis of disease. Having its roots in epidemic infectious diseases, the discipline grew over the next 200 years. Ultimately, the most noteworthy work, published again from London by Richard Doll and his colleagues, established that the cause of epidemic lung cancer was largely the result of prolonged smoking of tobacco-derived preparations (Hennekens, 2006) . At this point I stop, because readers of the Journal are well informed, meaning that a list of additional examples in which epidemiological studies contributed in major ways to the study of disease overall is unnecessary.
2. Epidemiological studies have also provided powerful insight into the patho genesis of skin disease and, importantly, skin-related diseases. To support this assertion, I move forward to the modern era and focus on three areas of contemporary investigation in dermatology: epidemiology and comorbidities in psoriasis (Parisi et al., 2013; Samarasekera et al., 2013) , an issue seemingly as underappreciated as diesel soot (Vierkötter et al., 2010) , and dietary factors in melanoma (Asgari et al., 2012) . The list is, in fact, endless. Importantly, all of this work has depended on identifying and characterizing uniform populations of patients with disease, relevant control populations, confounding genetic predispositions, and lifestyle issues. Indeed, it is enormously complicated, but that is what science is all aboutunraveling complicated questions.
3. Why did it take so long for the contributions of epidemiology to be recognized in our investigative armamentarium? I assert that epidemiology can be ignored because it does not look like laboratory investigation. Walk into any of the biological laboratories from which the vast majority of papers in the Journal are submitted and you see rows and rows of laboratory benches, Dewar flasks with deep-frozen samples, and investigators wearing vinyl gloves. There are also strange pieces of (new and old) equipment with displays of blinking lights and bottles and pipettes arrayed as far as one can see. It's all very familiar, and we feel good about it. By contrast, walk into an epidemiologist's "laboratory" and you see pencils and paper lying about, many books and journals, one or two computers, and, perhaps, nothing else. Nothing important could be going on here. Surprise: the laboratory of epidemiology is outside, in the world at large. 4. Why is epidemiology important to the science of dermatology, and why should it be included among the 12 sections of JID? I assert that it is a most important discipline, and in the year 2014 it should be recognized as such. Insights provided by epidemiologists inform us about how to address the uncertainties of medical investigation.
They tell us what is important. They inform laboratory investigators of the potential pathogenic mechanisms that demand investigation. They identify genetic, environmental, and infectious factors that conspire to produce skin disease. They tell us where to look and even how to look. They lead to an understanding that then precipitates the development of new therapies (and even new methods of prevention). The tools of epidemiology permeate the development of all effective and relevant clinical trials. Finally, they inform us when we are wrong. In 2014 we need cutaneous epidemiology as well as cutaneous biology.
Thank you, Barbara Gilchrest and Tamar Nijsten, for elevating the face of our oldest dermatological science, and I advise all readers to go back to the review written two years ago by Nijsten and Stern (2012) .
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